Skip to main content
. 2016 Dec 14;16(4):782–790. doi: 10.1038/mt.2008.1

Table 1.

Patient baseline characteristics and treatments

Patient no. Age (years)/ sex AJCC status Primary tumor sites Sites of metastates Previous therapy (cycles) Aex dose (µg) Vaccination (times)
Aex A1 36/M IV Colon Liver F4a (12) 100 4
A2 56/M IV Rectum Liver, lung, bone F4 (12) + 40 Gy 100 3
A3 45/F III Colon No Surg + F4 (12) 100 4
A4 60/F IV Colon Liver, lung De-Gb (12) + 40 Gy 100 4
A5 67/M IV Colon Omentum F4 (12) 100 4
B1 50/F IV Colon Liver, LN F4 (12) + 45 Gy 200 4
B2 55/M IV Colon Liver F4 (12) + 45 Gy 200 4
B3 42/F IV Colon Lung F6c (12) + 45 Gy 200 4
B4 61/M IV Colon Liver, spleen F4 (12) + 50 Gy 200 4
B5 49/M IV Rectum Peritoneum Fd (6) 200 4
C1 37/M IV Colon Mesenterium F (6) 300 4
C2 69/M IV Colon Liver, LN XELOXe (6) + 30 Gy 300 4
C3 57/F III Rectum No Surg + F4 (12) 300 4
C4 54/F IV Rectum Liver F4 (12) + 50 Gy 300 4
C5 47/M IV Colon Liver, lung, bone, LN F6 (12) + 45 Gy 300 2
D1 59/M IV Colon Omentum F4 (12) 500 4
D2 62/F III Colon No Surg + F4 (12) 500 4
D3 45/M IV Colon Lung, liver F6 (12) + 30 Gy 500 4
D4 48/F IV Colon Lung F4 (12) + 40 Gy 500 4
D5 51/M IV Colon Liver F6 (12) + 40 Gy 500 4
E1 39/M IV Rectum Lung F6 (12) + F (4) + 50 Gy 100 4
E2 55/M IV Colon Liver F4 (12) 100 4
Aex + GM-CSF E3 42/F IV Colon Liver, spleen, ovaries F (12) + 50 Gy 100 4
E4 65/F IV Colon Liver F4 (12) + 45 Gy 100 4
E5 50/M IV Colon Omentum F4 (12) 100 4
F1 58/F IV Colon Lung, liver F4 (12) + 45 Gy 200 4
F2 53/M IV Rectum Liver, omentum F4 (12) + 45 Gy 200 4
F3 49/F IV Colon Lung, liver, bone F4 (12) + F (6) + 45 Gy 200 4
F4 51/F IV Colon Omentum F6 (12) 200 4
F5 60/M III Colon Liver Capecitabinef (6) 200 4
G1 66/M IV Colon Bone, INa De-G (12) + 40 Gy 300 4
G2 64/F IV Colon Liver, spleen, pelvis F4 (12) 300 4
G3 51/F IV Colon Omentum AIOg (6) 300 4
G4 50/M IV Colon Liver F4 (12) 300 4
G5 47/M IV Colon Lung, liver F6 (12) + 45 Gy 300 4
H1 40/M IV Colon Lung, liver, LN F4 (12) + F (12) + 30 Gy 500 3
H2 46/M IV Colon Liver F4 (12) + 40 Gy 500 4
H3 62/F IV Colon Omentum XELOX (6) 500 4
H4 56/F IV Colon Lung F4 (12) + 40 Gy 500 4
H5 55/M IV Rectum Lung, liver, bone F4 (12) 500 4

Abbreviations: Aex, ascites-derived exosomes; AJCC, American Joint Committee on Cancer; F, female; GM-CSF, granulocyte-macrophage colony-stimulating factor; LN, lymph node; M, male; Surg, surgery.

a

F4 stands for FOLFOX4 regimen; oxaliplatin (85 mg/m2, IV on day 1); leucovorin (200 mg/m2, IV on days 1 and 2); 5-fluorouracil (400 mg/m2, IV on days 1 and 2); and 5-fluorouracil (600 mg/m2, continuous infusion (CI on days 1 and 2). The regimen was repeated every 2 weeks. bDe-G stands for De-Gramont regimen; leucovorin (400 mg/m2 IV on days 1 and 2) and 5-fluorouracil (400 mg/m2, IV on days 1 and 2, plus 600 mg/m2 5-fluorouracil via CI on days 1 and 2). The regimen was repeated every 2 weeks. cF6 stands for FOLFOX6 regimen: oxaliplatin (100 mg/m2, IV on day 1); leucovorin (400 mg/m2, IV on day 1) and 5-fluorouracil (400 mg/m2 (IV) plus 600 mg/m2 5-fluorouracil bolus on days 1 and 2,400-3,000 mg/m2 5-fluorouracil via CI over 46 hours). The regimen was repeated every 2 weeks. dF stands for FOLFIRI regimen (Douillard); irinotecan (180 mg/m2, IV on day 1); leucovorin (200 mg/m2 IV on days 1 and 2); and 5-fluorouracil (400 mg/m2, IV on days 1 and 2, plus 600 mg/m2 5-fluorouracil via CI >22 hours on days 1 and 2). This regimen was repeated every 2 weeks. eXELOX regimen: oxaliplatin (130 mg/m2, IV on day 1); capecitabine (1,000 mg/m2, PO (bid, total dose was ~2,000 mg/m2/day) on days 1-14). This regimen was repeated every 3 weeks. ‘Capecitabine regimen: capecitabine (1,000 mg/m2, PO (bid, total dose was ~2,000 mg/m2/day) on days 1-14). This regimen was repeated every 3 weeks. gAIO regimen. leucovorin (500 mg/m2, IV once per week); and 5-fluorouracil (2,000 mg/m2, CI once per week). This regimen was repeated every 3 weeks.